MonotherapyFulvestrant Sandoz® is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: - Not previously treated with endocrine therapy,or - With disease relapse on or after adjuvant endocrine therapy;or - disease progression on endocrine therapyCombination Therapy Fulvestrant Sandoz® is indicated for the treatment of:- HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- HR-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.